Immunovant unveils positive early data for PhII Graves' disease drug
Immunovant’s drug for Graves’ disease showed a response rate that exceeded 50% in an initial cohort of patients in an ongoing 24-week Phase II clinical trial, the company announced late Thursday afternoon.
The company’s stock $IMVT rose 11.47% premarket while Roivant, which has a major stake in the company, also saw a 5% $ROIV increase.
In the open-label trial, patients who are already on an anti-thyroid medication receive once-weekly injections of 680 mg batoclimab for 12 weeks, followed by once-weekly 340 mg injections of the candidate for another 12 weeks. The treatment response that Immunovant is looking for is a normalization of T3 and T4 hormone levels without increasing the dose of the anti-thyroid medication.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
